Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Immune and inflammation-related factors alteration as a biomarker for predicting prognosis and responsiveness to PD-1 monoclonal antibody in patients with recurrent cervical cancer

ABSTRACT: Purpose: We aimed to elucidate the potential mechanisms of effective responsiveness to PD-1 monoclonal antibody and evaluate more reliable biomarkers for improving the predictive utility of the dominant populations of recurrent cervical cancer (RCC) to receive immunotherapy. Methods: Peripheral blood samples of PD-L1 positive patients with RCC treated with second-line PD-1 monoclonal antibody were collected prior to treatment initiation and after the treatment. Differentially expressed genes (DEGs) were analyzed between partial response (PR) patient and progressive disease (PD) patients.

ORGANISM(S): Homo sapiens

PROVIDER: GSE205247 | GEO | 2022/10/05

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Immune and inflammation-related factors alteration as a biomarker for predicting prognosis and responsiveness to PD-1 monoclonal antibody in patients with recurrent cervical cancer

Project description:Immune and inflammation-related factors alteration as a biomarker for predicting prognosis and responsiveness to PD-1 monoclonal antibody in patients with recurrent cervical cancer

| PRJNA844275 | ENA

Features and protective efficacy of human monoclonal antibodies targeting M. tuberculosis arabinomannan

Project description:Human antibody responses to AM/LAM are heterogenous and knowledge of reactivity to specific glycan epitopes at the monoclonal level is limited. Using novel glycan arrays, we characterized a very high affinity monoclonal antibody P1AM25 to AM/LAM, determined this mAb recognized distinct glycan epitopes from other anti-AM/LAM mAbs reported.

2023-11-08 | GSE218873 | GEO

Human RP105 monoclonal antibody enables the production of antigen-specific antibody

Project description:Human RP105 monoclonal antibody enables the production of antigen-specific antibody

| PRJNA1006628 | ENA

Project description:Assessing biosimilarity of Trastuzumab monoclonal antibody therapeutics using RNA sequencing

| PRJNA667165 | ENA

Monoclonal Antibody Targeting Pear1 for Pulmonary Fibrosis Therapy [scRNA-seq]

Project description:Monoclonal Antibody Targeting Pear1 for Pulmonary Fibrosis Therapy [scRNA-seq]

| PRJNA761269 | ENA

Effect of a CD28H agonistic monoclonal antibody on NK cells

Project description:Effect of a CD28H agonistic monoclonal antibody on NK cells

| PRJNA638872 | ENA

Whole Exome Predictors Immune Checkpoint Therapy Response in Renal Cell Carcinoma

Project description:<p>Immune checkpoint therapies, including monoclonal antibodies to programmed cell death-1 (PD-1) and cytotoxic % lymphocyte associated protein-4 (CTLA-4), yield durable clinical responses across many tumor types, including metastatic melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). However, predictors of response to these therapies in RCC are still unknown. Genomic characterization of large clinical cohorts of patients treated with anti-CTLA-4 and anti-PD-1 agents in melanoma and NSCLC have suggested that high mutational burden, high neoantigen burden, and high expression of certain genes in pre-treatment tumors may be associated with patient response to these therapies. In this study, we sought to investigate genomic predictors of response to anti-PD1 therapy in metastatic RCC in two independent clinical cohorts using whole exome and whole transcriptome sequencing.</p>

| phs001493 | dbGaP

Evaluation of anti-tumorigenic effects of anti-Lipocalin2 (anti-LCN2) monoclonal antibody against human cervical cancer xenografts in athymic nude mice

Project description:This study investigated the impact of an anti-LCN2 monoclonal antibody on STR-authenticated HeLa cells using a xenograft model in athymic nude mice. Treatment of tumors with anti-LCN2 antibody resulted in 39 – 60% reduction in tumor volume. RNA extracted from the tumors post-treatment was sequenced and aligned to human and mouse genome separately. Differential expression analysis of human mapped overexpressed genes in treated tumor revealed suppression of pro-tumorigenic TNF- and IL17 signalling pathways, whereas the corresponding mouse-mapped genes indicated pathways including activation of T-cells and T-cell mediated killing in treated tumors. M2 mouse macrophage markers showed a decline under treatment signifying tumor regression. This observed T-cell activation and debilitation of M2 mouse macrophages by anti-LCN2 underlies its potential as an immune sensitizer that can potentially devour tumor cells through T-cell mediated cytotoxicity.

2023-12-31 | GSE242667 | GEO

LHRH Receptor Monoclonal Antibody 4F3B10 Induces Apoptosis of HeLa Cells

Project description:In this study, based on microarray hybridization and the detections of RTqPCR and Western Blotting, we have shown that HeLa cells treated with LHRH receptor monoclonal antibody 4F3B10 increased protein expressions in Fas signaling pathway, which provided a novel route for the gene therapy of HeLa cells.

2017-03-06 | GSE95695 | GEO

Human monoclonal antibodies to M. tuberculosis arabinomannan recognize distinct glycan epitopes - implications for TB diagnostics and research

Project description:Human antibody responses to AM/LAM are heterogenous and knowledge of reactivity to specific glycan epitopes at the monoclonal level is limited. Using novel glycan arrays, we characterized very high affinity monoclonal antibodies to AM/LAM, determined these mAbs are non-competing, and recognized distinct glycan epitopes. distinct from other anti-AM/LAM mAbs reported.

2021-07-21 | GSE180517 | GEO